Redeye ceases its coverage of Alelion following the bankruptcy and delisting of the shares from Nasd...
The Swedish authority exercises an option worth SEK13.
STENOCARE announced on November 6th an updated guidance for 2023 and 2024 as well as sales in Q3-23,...
Redeye makes a slight downward adjustment to its Q3 estimates following some additional data points.
Redeye ger en kort kommentar om försäljningssiffrorna för Leqembi under Q3.
Stark utveckling under kvartalet med ökade hyresintäkter.
Redeye saw a report that came in more or less as expected.
Paper EBITDA PLN 97m vs. ABGSCe PLN 65m Beat driven by higher volumes and lower costs Early signs of...
Redeye provides an initial take on Enzymatica’s Q3 2023 report.
Redeye sees a solid Q3 report from Hanza, beating our EBITA forecast by 13%.
Cibus posted Q3 net operating income of EUR 31.0m, up 18% y/y but included as much as EUR 2.
With the number of cruise vessel calls down by 51% y/y in Q3, the quarterly results are unlikely to ...
Redeye comments on Better Collective’s acquisition of Playmaker Capital, which is a Toronto-based di...
Redeye saw sales that were in line with our expectations.
Callidita’s strict Tarpeyo (US) product growth is 130% in Q3, and the recorded Q3 sales are 12% belo...
Redeye provides a comment following Faron’s announcement of the initiation of the phase II part of t...
Exel has taken actions to recover earnings. In our view wind power orders should drive at least some...
Redeye provides a preview ahead of Embracer Group’s Q2 2023/24e report, due on 16 November.
SEK 75m from rights issue leads to project re-prioritisation Primary focus on GLP-1 RA space (NEX-22...
Scandinavian Astor Group publicerade den 6 november år 2023 bolagets delårsrapport för tredje kvarta...
